People: Helix Biomedix Inc (HXBM.OB)

HXBM.OB on OTC BB

0.34USD
8 Feb 2010
Price Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.34
Open
--
Day's High
$0.34
Day's Low
$0.34
Volume
861
Avg. Vol
1,356
52-wk High
$0.59
52-wk Low
$0.16

view people for:

Summary

Name Age Since Current Position
Beatty, R. Stephen 59 2008 President, Chief Executive Officer, Chief Financial Officer, Director
Falla, Timothy 43 2001 Vice President, Chief Scientific Officer
Carmichael, Robin 52 2007 Vice President - Marketing and Business Development
Miller, Jeffrey 61 1999 Director
Caudill, Randall 62 2001 Director
Wilds, Daniel 60 2002 Director
Fiddes, John 57 2003 Director
Seidman, Barry 63 2004 Director
Cohen, Richard 58 2005 Director
O'Connor, David 73 2006 Director
Clifford, John 66 2007 Director
» Insider Trading

Biographies

Name Description
Beatty, R. Stephen R. Stephen Beatty has served as President and Chief Executive Officer and as a member of board of directors of Helix BioMedix, Inc. since May 1999 and has served as acting Chief Financial Officer since June 2008. Prior to joining the company, Mr. Beatty established and operated Beatty Finance, Inc., a private financial services company. Mr. Beatty is currently President and a director of Beatty Finance but does not have day-to-day responsibilities in those capacities. Mr. Beatty holds a B.S. in Mathematics from the University of South Alabama and an M.B.A. from the University of New Orleans.
Falla, Timothy Timothy J. Falla, Ph.D. has served as Vice President and Chief Scientific Officer of Helix BioMedix, Inc. since June 2001. From 1998 until 2001, Dr. Falla was Principal Scientist with IntraBiotics Pharmaceuticals, Inc. where he led a multi-disciplinary scientific research team focused on antibacterial drug discovery and development. Dr. Falla holds a B.S. in Applied Biology from the University of Wales, and a Ph.D. in Molecular Biology and Infectious Disease from Oxford University and the University of Wales.
Carmichael, Robin Robin L. Carmichael is Vice President, Marketing and Business Development of Helix BioMedix, Inc. He joined in October 2007 and serves as Vice President, Marketing and Business Development. From April 2007 to October 2007, Ms. Carmichael was the Chief Operating Officer of DERMAdoctor, Inc., a company specializing in developing and selling over-the-counter drugs and cosmeceuticals. Prior to joining DERMAdoctor, Inc., from 1998 to September 2006, Ms. Carmichael served as Vice President of Marketing first with ProCyte Corporation and then with Photomedex, Inc. following its acquisition of ProCyte in 2005 and as a consultant to the same company from January to June 2007. From 1993 to 1998, she held various marketing and clinical research positions of increasing responsibility with ProCyte. Ms. Carmichael holds a B.S. in Nursing from Seattle University and attended the UCLA Anderson Graduate School of Executive Management.
Miller, Jeffrey Jeffrey A. Miller, Ph.D has served as a member of board of directors Helix BioMedix, Inc. since December 1999. He is the President and Chief Executive Officer of each of Capital Markets Research, Inc., Gas-Lock Advisors, LLC and New Arc Investments, Inc., and serves of the board of directors of Think-a-Move Ltd. Dr. Miller has advised venture capital investors for the last six years. He is a principal in Katz-Miller Ventures, LLC, which provided financial consulting services to in the past. Dr. Miller holds a B.A. in Political Science from Bowling Green State University and a Ph.D in Political Science from the University of Michigan.
Caudill, Randall Randall L-W. Caudill, D. Phil. has served as a member of board of directors of Helix BioMedix, Inc. since December 2001. Dr. Caudill is the founder and President of Dunsford Hill Capital Partners, Inc., a financial consulting firm serving early-stage health care and technology companies. Dr. Caudill currently serves on the boards of directors of SCOLR Pharma, Inc. (AMEX:DDD), a biopharmaceutical company focusing on the controlled release of pharmaceuticals and nonprescription supplements and Ramgen Power Systems, Inc., a company committed to the development of high performance compressor and expander products and components based upon advanced supersonic technology principles and practices, as well as a number of not-for-profit entities. He received an M.P.P.M. (Master’s in Public and Private Management) from Yale University and a D. Phil. from Oxford University, where he was a Rhodes Scholar.
Wilds, Daniel Daniel O. Wilds has served as a member of board of directors of Helix BioMedix, Inc. since December 2002. From August 2003 to December 2008, Mr. Wilds served as President, Chief Executive Officer and a director of SCOLR Pharma, Inc. (AMEX:DDD), a biopharmaceutical company focusing on the controlled release of pharmaceuticals and nonprescription supplements. From 1998 until 2003 he served as President of Northwest Biotherapeutics, Inc., a company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. Mr. Wilds was President and Chief Executive Officer of Shiloov Biotechnologies (USA), Inc. from July 1997 to January 1998. Mr. Wilds holds a B.A. in Public Administration from California State University, Los Angeles and an M.B.A. from Northwestern University.
Fiddes, John John C. Fiddes, Ph.D has served as a member of board of directors of Helix BioMedix, Inc. since March 2003. Since January 2005, Dr. Fiddes has served as a consultant to a number of biotechnology companies. Prior to that, Dr. Fiddes was the Vice President of Research, Health Care, for Genencor International, Inc., a diversified biotechnology company that develops products and services for the bioproducts and health care markets, from June 2003 to December 2005. Dr. Fiddes served as the Chief Executive Officer of Tao Biosciences, LLC from March 2002 to December 2002. From 1994 until September 2001, Dr. Fiddes held executive positions at IntraBiotics Pharmaceuticals, Inc., a biopharmaceutical company developing antibacterial and antifungal products for the treatment and prevention of serious infectious diseases, serving as Vice President of Research and Development and subsequently Chief Technical Officer and Vice President of Preclinical Research. Dr. Fiddes holds a B.S. in Molecular Biology from the University of Edinburgh and a Ph.D in Molecular Biology from King’s College at Cambridge University. He did postdoctoral research as a Research Fellow at the University of California, San Francisco.
Seidman, Barry Barry L. Seidman has served as a member of board of directors of Helix BioMedix, Inc. since November 2004. Mr. Seidman has served as Chairman of the Board of Pax Holding Corporation, a full-service options, stock and futures clearing firm, since May 2001. Since 2006 Mr. Seidman has been a director of Think-a-Move Ltd. and since 2007 he has been a director of Performance Inc. For the preceding ten years, Mr. Seidman was an independent consultant in the securities industry. In prior years, Mr. Seidman was President and Chief Operating Officer of First Options of Chicago and a Partner of Spear Leeds and Kellogg. He also served in various positions at The Options Clearing Corporation, culminating as First Vice President of National Operations. In the past he has served on the Board of Governors of the Philadelphia Stock Exchange and on the board of directors of The Options Clearing Corporation. Mr. Seidman is a graduate of St. John’s University with a B.S. in accounting.
Cohen, Richard Richard M. Cohen has served as a member of board of directors of Helix BioMedix, Inc. since December 2005. Since 1996, Mr. Cohen has been the President of Richard M. Cohen Consultants, a financial services consulting company that assists public and private companies with their corporate finance and corporate governance needs. Since 2003, Mr. Cohen has served as a director of Dune Energy, Inc. (AMEX:DNE), an oil and gas exploration and production company for which he served as Chief Financial Officer from November 2003 to April 2005. He also currently serves as corporate secretary and a member of the compensation committee of Dune. Since 2007, Mr. Cohen has been a director and a member of the audit committee of Rodman & Renshaw Capital Group, Inc. (NASDAQ:RODM) and since May 2007 he has been a director of Pinpoint Recovery Solutions Corp. (OTCBB:PPNT). Mr. Cohen is a Certified Public Accountant (New York State). He received a B.S. from the University of Pennsylvania (Wharton) and an M.B.A. from Stanford University.
O'Connor, David David M. O'Connor has served as a member of board of directors of Helix BioMedix, Inc. since March 2006. Since 1998, Mr. O’Connor has been a consultant with Westfield Consultants Group, an independent business consulting firm. From 1992 to 1998, Mr. O’Connor was the President and a member of the board of directors of Merle Norman Cosmetics International, and prior to that he served as an executive officer of InterCare Medical Group & Emergency Department Physicians Medical Group, Visage Beauté Cosmetics, and Merle Norman Cosmetics, Inc. In addition, Mr. O’Connor served as the Chairman of the board of directors of the Robert F. Kennedy Medical Center and as President and a member of the board of directors of the Beauty Industry West Trade Association. Mr. O’Connor holds a B.S. from the University of Oregon and an M.H.A. from the University of Southern California.
Clifford, John John F. Clifford has served as a member of board of directors of Helix BioMedix, Inc. since August 2007. Mr. Clifford is a consultant in the aesthetic and dermatology markets. He was Executive Vice President of Dermatology for PhotoMedex, Inc. from May 2005 until June 2006 following its acquisition of ProCyte Corporation. He was President, Chief Executive Officer and Chairman of ProCyte Corporation from 1996 until May 2005. Before joining ProCyte Corporation, Mr. Clifford was the President of Orthofix, Inc. U.S., which acquired American Medical Electronics, Inc., where he was Chief Executive Officer. From 1989 to 1994, he was employed by Davis and Geck, Inc. as Division Vice President. From 1964 to 1989, Mr. Clifford held various sales and marketing positions at Ethicon Inc. and Iolab Corporation, both Johnson & Johnson companies. Mr. Clifford holds a B.S. in Economics from Villanova University and an M.B.A. in Finance from Drexel University.

Basic Compensation

Name Fiscal Year Total
Beatty, R. Stephen 453,692
Falla, Timothy 321,937
Carmichael, Robin 242,446
Miller, Jeffrey --
Caudill, Randall --
Wilds, Daniel --
Fiddes, John --
Seidman, Barry --
Cohen, Richard --
O'Connor, David --
Clifford, John --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Beatty, R. Stephen 784,000 111,600
Falla, Timothy 380,000 0
Carmichael, Robin 0 0
Miller, Jeffrey 0 0
Caudill, Randall 0 0
Wilds, Daniel 0 0
Fiddes, John 0 0
Seidman, Barry 0 0
Cohen, Richard 0 0
O'Connor, David 0 0
Clifford, John 0 0

Insider Trading

» Full list on Insider Trading
view people for: